Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Return on Invested Capital (2022 - 2025)

Sutro Biopharma's Return on Invested Capital history spans 4 years, with the latest figure at 3.15% for Q3 2025.

  • For Q3 2025, Return on Invested Capital rose 429.0% year-over-year to 3.15%; the TTM value through Sep 2025 reached 3.15%, up 429.0%, while the annual FY2024 figure was 2.43%, 187.0% down from the prior year.
  • Return on Invested Capital for Q3 2025 was 3.15% at Sutro Biopharma, up from 3.31% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 3.15% in Q3 2025 and bottomed at 3.31% in Q4 2024.
  • The 4-year median for Return on Invested Capital is 0.88% (2023), against an average of 0.72%.
  • The largest annual shift saw Return on Invested Capital plummeted -252bps in 2024 before it skyrocketed 429bps in 2025.
  • A 4-year view of Return on Invested Capital shows it stood at 0.56% in 2022, then plummeted by -41bps to 0.79% in 2023, then crashed by -320bps to 3.31% in 2024, then skyrocketed by 195bps to 3.15% in 2025.
  • Per Business Quant, the three most recent readings for STRO's Return on Invested Capital are 3.15% (Q3 2025), 3.31% (Q4 2024), and 1.15% (Q3 2024).